Abbott Abbott Preparing for COVID-19 Testing Uncertainty in 2022 Premium During the firm's earnings call, management emphasized how the ups and downs of the pandemic made predicting the year particularly difficult. Abbott Q4 Diagnostics Revenues Grow 3 Percent, Full-Year Revenues up 25 Percent The Abbott Park, Illinois-based firm's global COVID-19-related sales were $2.3 billion in the fourth quarter, including $2.1 billion from rapid testing. JPM Healthcare Conference Day 2: Thermo Fisher, BD, SomaLogic, Myriad, Oxford Nanopore, More Highlights of the second day included Myriad Genetics' new oncology testing service and more details on SomaLogic's partnership with Illumina. People in the News: New Appointments at NIH, Abbott, Talis Biomedical, More Abbott Sees Continued Demand for SARS-CoV-2 Rapid Tests Despite Expected Decline in Cases Premium The firm more than doubled its COVID-19 testing-related revenues during Q3 compared to a year ago. Around 84 percent of the revenues were for rapid screening tests. Oct 20, 2021 Abbott Q3 Diagnostics Revenues Rise 48 Percent on Core Lab, Rapid Diagnostics Sales Growth Oct 14, 2021 FDA Classifies Abbott SARS-CoV-2 Molecular Test Recall as Class I Due to False Positives Sep 17, 2021 FDA Warns of Potential False Positives With Abbott SARS-CoV-2 Molecular Tests Jul 22, 2021 Abbott Q2 Diagnostics Revenues Rise 63 Percent on COVID-19 Testing Demand Jun 1, 2021 Abbott Lowers FY21 Guidance as It Sees Sharp Decline in COVID-19 Test Revenue Apr 20, 2021 Abbott Q1 Diagnostics Revenues More Than Double on COVID-19 Testing Mar 11, 2021 Abbott Forms Global Coalition to Monitor, Prevent Future Pandemics Mar 5, 2021 Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections Feb 18, 2021 WHO Finds High Diagnostic Accuracy in Three Classes of MDx Technologies for TB Testing, Resistance Jan 27, 2021 Abbott Q4 Diagnostics Revenues up 111 Percent, FY20 Revenues up 9 Percent Nov 13, 2020 Abbott Enters $5B Credit Agreement Oct 21, 2020 Abbott Q3 Diagnostics Revenues Increase 38 Percent Oct 7, 2020 Abbott ID Now Study Data Confirms Test Sensitivity and Specificity Sep 21, 2020 FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test Sep 8, 2020 As Flu Season Nears, Dx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, Influenza Premium Aug 27, 2020 As Abbott Stock Rises on EUA for Antigen Test, Competitors' Shares Take a Hit Jul 21, 2020 AdvaMed Partners With Dx Companies to Create National COVID-19 Supply Registry Jul 17, 2020 Weathering COVID-19 Pandemic, Abbott Beats Analyst Q2 Expectations on Coronavirus Testing Demand Premium Jul 16, 2020 Abbott Q2 Diagnostics Revenues Rise 5 Percent, MDx Revenues Skyrocket Jun 12, 2020 In Brief This Week: Guardant Health, Illumina, Twist Bioscience, Hologic, InCellDx, More Load More Breaking News Epic Sciences, Biosplice Therapeutics Partner on Multiomic Profiling for Cancer Trials Hamilton, Pacific Biosciences Partner on Automating DNA Sample Prep Danaher Q4 Revenues Rise 21 Percent COVID-19 Severity Biomarker Candidates Revealed in RNA Sequencing Study Flatiron Health, Japanese Hospital Partner on Real-World GI Cancer Database Abbott Q4 Diagnostics Revenues Grow 3 Percent, Full-Year Revenues up 25 Percent The Scan Time to Act A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian. Fulgent Seeking Defamation Suit Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports. Speeding Gene-Edited Crops Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there. Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.